Exclude Patient Type Detail Header
No
Footnote
<sup>1</sup> <b>NIH 2023.</b> COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Last update 11/2/23. <a href=https://www.covid19treatmentguidelines.nih.gov/><u>Accessed 11/13/23</u></a>
<br><br>
<sup>2</sup> <b>IDSA 2023.</b> Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19. Last update 6/26/23. <a href=https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/><u>Accessed 11/13/23</u></a>
<br><br>
<sup>3</sup> <b>WHO 2023.</b> Therapeutics and COVID-19: Living Guideline. World Health Organization. Last update 1/13/23. <a href=https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2023.1><u>Accessed 3/15/23</u></a>
<br><br>
<sup>4</sup> Equivalent daily glucocorticoid dose may be substituted if dexamethasone unavailable.
<br><br>
<sup>5</sup> If dexamethasone contraindicated, consider remdesivir + baricitinib.
<br><br>
<sup>6</sup> If none of the preferred or alternative options are available or feasible to use, may use <a href=https://online.epocrates.com/e/deeplink/drugs/10a6515/Xeljanz><u>tofacitinib</u></a> or sarilumab IV.
<br><br>
<sup>7</sup> If neither baricitinib nor tocilizumab is available or feasible to use, may use <a href=https://online.epocrates.com/e/deeplink/drugs/10a6515/Xeljanz><u>tofacitinib</u></a> as an alternative to baricitinib, & sarilumab IV as an alternative to tocilizumab IV.
<br><br>
<sup>8</sup> If neither baricitinib nor IL-6 receptor blocker is available, may use ruxolitinib or <a href=https://online.epocrates.com/e/deeplink/drugs/10a6515/Xeljanz><u>tofacitinib</u></a>. Studies used ruxolitinib 5 mg PO bid x14 days.
<br><br>
<sup>2</sup> <b>IDSA 2023.</b> Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19. Last update 6/26/23. <a href=https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/><u>Accessed 11/13/23</u></a>
<br><br>
<sup>3</sup> <b>WHO 2023.</b> Therapeutics and COVID-19: Living Guideline. World Health Organization. Last update 1/13/23. <a href=https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2023.1><u>Accessed 3/15/23</u></a>
<br><br>
<sup>4</sup> Equivalent daily glucocorticoid dose may be substituted if dexamethasone unavailable.
<br><br>
<sup>5</sup> If dexamethasone contraindicated, consider remdesivir + baricitinib.
<br><br>
<sup>6</sup> If none of the preferred or alternative options are available or feasible to use, may use <a href=https://online.epocrates.com/e/deeplink/drugs/10a6515/Xeljanz><u>tofacitinib</u></a> or sarilumab IV.
<br><br>
<sup>7</sup> If neither baricitinib nor tocilizumab is available or feasible to use, may use <a href=https://online.epocrates.com/e/deeplink/drugs/10a6515/Xeljanz><u>tofacitinib</u></a> as an alternative to baricitinib, & sarilumab IV as an alternative to tocilizumab IV.
<br><br>
<sup>8</sup> If neither baricitinib nor IL-6 receptor blocker is available, may use ruxolitinib or <a href=https://online.epocrates.com/e/deeplink/drugs/10a6515/Xeljanz><u>tofacitinib</u></a>. Studies used ruxolitinib 5 mg PO bid x14 days.
Detail Type
Text
Detail Text
Patient Type Detail Header (Long)
General mgmt